Allogene Therapeutics announces $175M common stock offering

Allogene Therapeutics (ALLO) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175M of shares of its common stock. All of the shares are being offered by Allogene. Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. Goldman Sachs & Co., Jefferies and TD Cowen are acting as the joint book-running managers for the offering. TPG Capital BD is acting as co-manager for the offering.